China dairy firm Junlebao's latest infant formula launch, findings of Swisse's krill oil RCT on knee osteoarthritis, as well as Vinamilk's and H&H's insights on Vietnam's infant formula market are some of the most popular stories in August.
China's Junlebao Dairy Group has launched a new infant formula, which is said to contain one of the highest lactoferrin content in the market.
Swisse will be applying for new therapeutic claims related to knee health under the nascent 'assessed listed' medicines scheme in Australia for its krill oil supplement, following positive human clinical trial findings.
Human milk oligosaccharide (HMO) is one of the hottest and most commonly seen ingredients in Vietnam's infant formula products these days, according to Vietnam homegrown firm Vinamilk and Hong Kong-headquarted Health & Happiness Group (H&H Group), which only entered the market in June.
Kao will introduce its first Food with Function Claims (FFC) product in Japan for its skincare and cosmetic brand est on October 7.
MD Pharmaceuticals, a Singapore-based healthcare distributor and marketer, has developed a new vitamin D supplement with DSM, which is said to be faster acting for immune health.
Blackmores will beef up its local inventory for the 13 markets that it currently operates in, design new pack sizes for markets such as Thailand, and target eye health growth in China over the next year, the company's CEO told NutraIngredients-Asia.
New Zealand's Ministry of Health is intending to regulate natural health products via a self-assessment / declaration process, a move welcomed by the local industry body.
The cGP Lab Ltd, a New Zealand firm specialising in developing dietary supplements containing cyclic glycine-proline (cGP) – a molecule extracted from New Zealand grown blackcurrants – is eyeing China's healthy ageing market with its products.
A total of 34.4% of Japanese female nursing professionals regularly consume supplements, especially those who are older, non-obese or pregnant, new data has shown.
China's State Administration of Market Regulation (SAMR) is seeking to expand the current list of approved health claims and has convened a public consultation on potential new additions.
